Hypoalbuminemia affects the spatio-temporal tissue distribution of ochratoxin A in liver and kidneys: consequences for organ toxicity.
Albumin binding
Intravital imaging
Mycotoxins
Pharmacokinetics
Toxicokinetics
Journal
Archives of toxicology
ISSN: 1432-0738
Titre abrégé: Arch Toxicol
Pays: Germany
ID NLM: 0417615
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
28
06
2022
accepted:
03
08
2022
pubmed:
14
8
2022
medline:
5
10
2022
entrez:
13
8
2022
Statut:
ppublish
Résumé
Hypoalbuminemia (HA) is frequently observed in systemic inflammatory diseases and in liver disease. However, the influence of HA on the pharmacokinetics and toxicity of compounds with high plasma albumin binding remained insufficiently studied. The 'lack-of-delivery-concept' postulates that HA leads to less carrier mediated uptake of albumin bound substances into hepatocytes and to less glomerular filtration; in contrast, the 'concept-of-higher-free-fraction' argues that increased concentrations of non-albumin bound compounds facilitate hepatocellular uptake and enhance glomerular filtration. To address this question, we performed intravital imaging on livers and kidneys of anesthetized mice to quantify the spatio-temporal tissue distribution of the mycotoxin ochratoxin A (OTA) based on its auto-fluorescence in albumin knockout and wild-type mice. HA strongly enhanced the uptake of OTA from the sinusoidal blood into hepatocytes, followed by faster secretion into bile canaliculi. These toxicokinetic changes were associated with increased hepatotoxicity in heterozygous albumin knockout mice for which serum albumin was reduced to a similar extent as in patients with severe hypoalbuminemia. HA also led to a shorter half-life of OTA in renal capillaries, increased glomerular filtration, and to enhanced uptake of OTA into tubular epithelial cells. In conclusion, the results favor the 'concept-of-higher-free-fraction' in HA; accordingly, HA causes an increased tissue uptake of compounds with high albumin binding and increased organ toxicity. It should be studied if this concept can be generalized to all compounds with high plasma albumin binding that are substrates of hepatocyte and renal tubular epithelial cell carriers.
Identifiants
pubmed: 35962801
doi: 10.1007/s00204-022-03361-8
pii: 10.1007/s00204-022-03361-8
pmc: PMC9525345
doi:
Substances chimiques
Mycotoxins
0
Ochratoxins
0
Serum Albumin
0
ochratoxin A
1779SX6LUY
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2967-2981Informations de copyright
© 2022. The Author(s).
Références
Toxins (Basel). 2018 Jun 22;10(7):
pubmed: 29932113
Hepatology. 2019 Feb;69(2):666-683
pubmed: 30102412
J Pharm Sci. 1977 Apr;66(4):447-65
pubmed: 323460
Hepatology. 2021 Apr;73(4):1531-1550
pubmed: 32558958
Cells. 2019 Dec 02;8(12):
pubmed: 31810365
Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):308-13
pubmed: 21173249
IEEE Trans Image Process. 1998;7(1):27-41
pubmed: 18267377
Front Physiol. 2014 Aug 12;5:299
pubmed: 25161624
Crit Rev Toxicol. 2011 Mar;41(3):187-212
pubmed: 21401326
Cells. 2021 Sep 23;10(10):
pubmed: 34685496
Toxins (Basel). 2010 Jun;2(6):1381-98
pubmed: 22069643
Mycotoxin Res. 2017 Feb;33(1):39-47
pubmed: 27830509
J Pharmacol Exp Ther. 1996 Dec;279(3):1507-13
pubmed: 8968376
Mol Aspects Med. 2012 Jun;33(3):209-90
pubmed: 22230555
Arch Toxicol. 2021 Jun;95(6):2163-2177
pubmed: 34003344
EXCLI J. 2016 Dec 23;15:872-874
pubmed: 28275323
Food Chem Toxicol. 1985 Oct;23(10):941-3
pubmed: 4065769
JPEN J Parenter Enteral Nutr. 2019 Feb;43(2):181-193
pubmed: 30288759
Cell Mol Gastroenterol Hepatol. 2021;11(4):909-933
pubmed: 33189892
Hepatology. 2022 May;75(5):1095-1109
pubmed: 34927748
IARC Monogr Eval Carcinog Risks Hum. 1993;56:489-521
pubmed: 8411629
J Hepatol. 2022 Jul;77(1):71-83
pubmed: 35131407
Crit Rev Toxicol. 2005 Jan;35(1):33-60
pubmed: 15742902
United European Gastroenterol J. 2021 May;9(4):427-437
pubmed: 34050619
Chem Biol Interact. 2006 Jan 5;159(1):18-46
pubmed: 16293235
Arch Toxicol. 2017 Mar;91(3):1335-1352
pubmed: 27999878
Nat Methods. 2019 Dec;16(12):1226-1232
pubmed: 31570887
Ann Hematol. 2016 Dec;95(12):2009-2015
pubmed: 27542957
Lancet. 1989 Dec 16;2(8677):1434-6
pubmed: 2574367
Food Chem Toxicol. 2018 Feb;112:320-331
pubmed: 29309824
Luminescence. 2013 Sep-Oct;28(5):726-33
pubmed: 22987806
Front Cell Dev Biol. 2021 Apr 29;9:633925
pubmed: 33996793
Arch Toxicol. 2018 Sep;92(9):2963-2977
pubmed: 30039229
Arch Toxicol. 2020 Jan;94(1):205-217
pubmed: 31919559
Eur J Clin Pharmacol. 1974 Jul 26;7(4):259-62
pubmed: 4851053
J Hepatol. 2021 Apr;74(4):819-828
pubmed: 33075344
Cell Rep. 2021 Aug 24;36(8):109526
pubmed: 34433051
Kidney Blood Press Res. 2005;28(5-6):307-10
pubmed: 16534226
Sci Rep. 2017 Jul 24;7(1):6224
pubmed: 28740200
Hepatol Int. 2021 Oct;15(5):1160-1173
pubmed: 34021479
J Natl Cancer Inst. 1985 Oct;75(4):733-42
pubmed: 3862905
Mycotoxin Res. 2020 Feb;36(1):1-10
pubmed: 31077038
Adv Drug Deliv Rev. 2017 Jul 1;116:73-91
pubmed: 28111348
Hepatol Commun. 2022 Jan;6(1):161-177
pubmed: 34558834
Nat Metab. 2021 Sep;3(9):1228-1241
pubmed: 34552267
Mol Nutr Food Res. 2009 Apr;53(4):467-78
pubmed: 19072886
Gan. 1978 Aug;69(4):599-600
pubmed: 710809
J Pers Med. 2021 Dec 01;11(12):
pubmed: 34945736